Literature DB >> 6089677

Neurochemical enzyme changes in Alzheimer's and Pick's disease.

W Meier-Ruge, P Iwangoff, K Reichlmeier.   

Abstract

Neurochemical investigations of the whole temporal lobe of cases with Alzheimer's disease (n = 15); 80.7 +/- 1.7 yr), Pick's disease (n = 3; 65 +/- 1.7 yr), and age-matched controls (n = 18; 74.7 +/- 2.6 yr), demonstrate that Alzheimer's and Pick's disease are primary degenerative brain diseases. The activities of glycolytic enzymes, ATPases, carbonic anhydrase, acetylcholinesterase and protein kinase were significantly lower in Alzheimer's and in Pick's disease than in age-matched controls. Pick's disease is characterised by a more pronounced reduction of the enzymes investigated, which is considered to be an expression of a more dramatic degenerative process. The differences between Alzheimer's disease and Pick's disease are quantitative.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089677     DOI: 10.1016/0167-4943(84)90007-4

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  23 in total

1.  Age-related defects in erythrocyte 2,3-diphosphoglycerate metabolism in dementia.

Authors:  Yury G Kaminsky; V Prakash Reddy; Ghulam Md Ashraf; Ausaf Ahmad; Valery V Benberin; Elena A Kosenko; Gjumrakch Aliev
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids.

Authors:  A A Farooqui; L Liss; L A Horrocks
Journal:  Metab Brain Dis       Date:  1988-03       Impact factor: 3.584

Review 3.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

4.  Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy.

Authors:  S J Kish; L Schut; J Simmons; J Gilbert; L J Chang; M Rebbetoy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

Review 5.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 6.  Carnosine and Related Peptides: Therapeutic Potential in Age-Related Disorders.

Authors:  José H Cararo; Emilio L Streck; Patricia F Schuck; Gustavo da C Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 7.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

Review 8.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

Review 9.  Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.

Authors:  D Allan Butterfield; Tanea Reed; Shelley F Newman; Rukhsana Sultana
Journal:  Free Radic Biol Med       Date:  2007-06-13       Impact factor: 7.376

10.  Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease.

Authors:  Rukhsana Sultana; Marzia Perluigi; Shelley F Newman; William M Pierce; Chiara Cini; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2010-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.